Qiuhua Luo

Dr. Qiuhua Luo


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2011 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
QLQiuhua Luo
Qiuhua Luo
JZJunming Zhao
Junming Zhao
XZXiangrong Zhang
Xiangrong Zhang
WPWeisan Pan
Weisan Pan

1 July 2019 in Cancer Letters
Verified
Journal Article
Closed access
QLQiuhua Luo
Qiuhua Luo
LZLing Zhang
Ling Zhang
CLCong Luo
Cong Luo
MJMingyan Jiang
Mingyan Jiang

14 February 2023 in ACS Nano
Verified
Journal Article
Closed access
XCXuchun Chen
Xuchun Chen
YCYing Cheng
Ying Cheng
QPQi Pan
Qi Pan
LWLan Wu
Lan Wu
XHXinyao Hao
Xinyao Hao
HLHeran Li
Heran Li

1 December 2016 in Journal of Controlled Release
Verified
Journal Article
Closed access
QLQiuhua Luo
Qiuhua Luo
PGPing Gong
Ping Gong
MSMengchi Sun
Mengchi Sun
LKLongfa Kou
Longfa Kou
VGVadivel Ganapathy
Vadivel Ganapathy
JSJin Sun
Jin Sun

1 March 2020 in Asian Journal of Pharmaceutical Sciences
Verified
Journal Article
Open access
LZLing Zhang
Ling Zhang
CSChengguang Sui
Chengguang Sui
WYWenhan Yang
Wenhan Yang
QLQiuhua Luo
Qiuhua Luo
Amino acid transporters, which play a vital role in transporting amino acids for the biosynthesis of mammalian cells, are highly expressed in types of tumors. Increasing studies have shown the feasibility of amino acid transporters as a component of tumor-targeting therapy. In this review, we focus on tumor-related amino acid transporters and their potential use in tumor-targeting therapy. Firstly, the expression characteristics of amino acid transporters in cancer and their relationship with tumor growth are reviewed. Secondly, the recognition requirements are discussed, focusing on the "acid-base" properties, conformational isomerism and structural analogues. Finally, recent developments in amino acid transporter-targeting drug delivery strategies are highlighted, including prodrugs and nanocarriers, with special attention to the latest findings of molecular mechanisms and targeting efficiency of transporter-mediated endocytosis. We aim to offer related clues that might lead to valuable tumor-targeting strategies by the utilization of amino acid transporters.

19 December 2016 in Biomaterials Science
Verified
Journal Article
Closed access
PDF file
QLQiuhua Luo
Qiuhua Luo
BYBin Yang
Bin Yang
WTWenhui Tao
Wenhui Tao
JLJia Li
Jia Li
LKLongfa Kou
Longfa Kou
JSJin Sun
Jin Sun
Tumor cells have an increased demand for amino acids to support their rapid growth and malignant metastasis. Transfer of amino acids across plasma membranes depends on several amino acid transporters that are highly upregulated in tumor cells and are promising targets for tumor cell-selective therapy. In this study, stealth liposomal systems functionalized with aspartate-polyoxyethylene stearate conjugate (APS) were developed for transporter-mediated targeted delivery to ATB0,+, which is overexpressed human lung cells. The resultant ATB0,+-targeting liposomes (APS-Lips) consisted of a liposome core and the surface coverage of the APS modifier had an optimized density of 10%. APS-Lips had a uniform particle size distribution and high encapsulation efficiency of docetaxel (DTX, >80%). APS modification had a negligible effect on the DTX release from liposomes. Compared with Taxotere and unmodified liposomes, APS-Lips showed increased intracellular delivery and antitumor potency against human lung cells. Furthermore, competitive endocytosis studies showed that the cellular uptake of APS-Lips was notably decreased in the presence of glycine, a typical substrate of ATB0,+, and was increased through adhesion to the cell membrane via transporter-substrate interactions. Finally, in vitro hemolysis and in vivo vascular irritation studies in rabbits confirmed the good blood compatibility and minimal vascular stimulation of the synthetic ATB0,+-targeting material APS. These results demonstrated that the aspartate-modified liposomes could be a promising nanocarrier for ATB0,+ transporter-mediated targeted drug delivery to treat lung cancer.